Our initiative focuses on designing and developing innovative tools and techniques to identify novel therapeutic targets, delivery mechanisms, and bioactive molecules with high potential for industry uptake and clinical translation. It is built on collective expertise in drug discovery research from across the University, underpinned by state-of-the-art infrastructure and input from industry and clinical advisory groups.
Through Sydney Analytical, we have a suite of facilities to support and accelerate early-stage drug discovery including:
Join the Drug Discovery Initiative's Translational Innovations Symposium on 20 June 2019, to hear from a diverse range of academics from the DDI membership and six short-listed ECR/MCR applicants of the 2019 DDI Initiative Seed Funding scheme. There will be opportunities to meet researchers and industry representatives working across all areas of the drug discovery pipeline. See the symposium program and register for this free event.
The Drug Discovery Initiative was officially launched on 10 Septemberlast month at the Charles Perkin Centre. The launch was attended by representatives from across the University, pharmaceutical industry and government, with talks from Professor Hugh Durrant Whyte (NSW Chief Scientist and Engineer), Dr Antonio Penna (Executive Director NSW Health), Lisa Daly (Program Manager Sydney Research), Dr Daniel Grant (CEO MTPConnect), Professor Duncan Ivison (DVC (Research) and Professor Peter Lay (Director Sydney Analytical). Read more about the launch.
While therapies and prognoses for most cancers have improved drastically over the last two decades, there is still huge potential for further improvement through the development of targeted interventions and treatments, and a better understanding of the genetic and molecular mechanisms of cancers. We are working to develop bioactive molecules that enhance the understanding, prevention, and treatment of cancers.
With incidences of drug resistance increasing across many infectious diseases, there is a pressing need to develop new and more effective treatments. Our researchers are working to overcome disease resistance by discovering new targets and lead compounds to tackle diseases such as tuberculosis, malaria and fungal infections.
Regulating the body’s inflammatory responses for treating pain and inflammation have applications in a growing list of disorders. Our research focuses on the identification and validation of novel targets implicated in pain, inflammation and autoimmunity, with potential applications in the understanding and treatment of cancers, central nervous system, metabolic and cardiovascular disorders.
Neurodegenerative and central nervous system disorders such as dementia and systemic pain, are becoming increasingly prevalent with increasing life-spans. We are working to identify targets and develop lead compounds that selectively modulate the central nervous system.
Diseases relating to metabolic and cardiovascular disorder, such as diabetes and obesity, represent a rapidly growing health problem in Australia and globally. Our researchers are pursuing therapeutic leads to target such diseases.
We work closely with the following centres and initiatives across these five disease focus areas: